Dr. Nita Limdi is a Professor at the University of Alabama at Birmingham. She is a clinical pharmacist, epidemiologist, and renowned researcher in pharmacogenomics and pharmacoepidemiology. Her research centers around the factors that influence drug responses, with a focus on anticoagulants…
Vancouver, Canada (May 13, 2022) – Innovation and differentiation continue to propel precision prescribing software company GenXys with accolades and commercial success in the US market. GenXys recently was named the 2022 Best Overall Medical Data Solution Provider by MedTech Breakthrough…
Pharmacogenetic Testing & EHR Integration Help Avoid Trial-and-Error Prescribing Vancouver, Canada (April 21, 2022): GenXys Health Care Systems, Inc., the global leader in precision prescribing software with embedded pharmacogenetic data, added a record five pharmacogenetic companies as customers in the first…
Adverse Drug Events (ADEs) annually account for more than 1 million emergency department visits, 2.2 million hospital admissions, 3.5 million physician office visits, and $136 billion in U.S. health care costs. In addition to being the #1 most costly hospital-acquired condition,…
References 1 – https://www.futuremedicine.com/doi/10.2217/pgs-2019-0134 2 – https://www.cdc.gov/medicationsafety/adult_adversedrugevents.html 3 – https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-14-73 4 – https://pubmed.ncbi.nlm.nih.gov/24798722/ 5 – https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling 6 – https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255642 7 – https://www.reuters.com/article/us-bristol-myers-sanofi-plavix-idUSKBN2AF1YI 8 – https://www.einnews.com/pr_news/560810526/pharmacogenomics-market-is-estimated-to-reach-usd-11-97-billion-by-2028-emergen-research#:~:text=RESEARCH%20%2D%20EIN%20Presswire-,Pharmacogenomics%20Market%20is%20estimated%20to%20reach,billion%20by%202028%3A%20EMERGEN%20RESEARCH&text=Pharmacogenomics%20Market%20trends%20%E2%80%93%20Growing%20demand%20for%20personalized%20therapy
General Update GenXys is one of the first groups to update our comprehensive precision prescribing algorithm to include the latest release from the Clinical Pharmacogenetics Implementation Consortium (CPIC) CYP2C19 Genotype and Clopidogrel Therapy, published January 19, 2022. We stay at the…
Vancouver, BC – GenXys Healthcare Systems Inc. (GenXys) is adding a new value dimension to Precision Genetics and the personalized health marketplace. Precision prescribing has become a leading method to bring pharmacogenetics (PGx) closer to the standard of care for certain…
Top Five Questions and Answers from Canada’s ‘Godfather’ of Life Sciences, Dr. Pieter Cullis You’ve been on the cutting edge of life sciences for many years in taking the ‘lab to the bedside’ to improve health – can you tell us…
Earlier this year, I decided to take the plunge and join the board of GenXys Health Care Systems (GenXys) as an independent board member. I have been intrigued by precision medicine for years, wondering why this has been historically slow to…
Vancouver, BC – GenXys Health Care Systems (GenXys), the award-winning precision prescribing company, today announced a partnership with Helix, a leading population genomics company working at the intersection of clinical care, research, and genomics. Together, the companies will be working to…